Clinical Trial Update: Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985 [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluating sodium thiosulfate eye drops (BYON5667) to reduce ocular toxicity in cancer patients treated with SYD985 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• SYD985 (trastuzumab duocarmazine)
• Sodium thiosulfate eye drops BYON5667 (sodium thiosulfate)

Snippet

Sponsor: Byondis B.V. | Conditions: Metastatic Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED